Kelvin W. GeeProfessor, Pharmacology |
|
|
Research Interests |
receptors, drug discovery, ion channels, GABA, nicotine | |
| URLs | Pharmacology Home Page | |
| Dr. Gee's Lab | ||
| See below for selected publications or click here for additional publication listings available via PUB MED | ||
|
Academic Distinctions | 1985, Who's Who in Frontier Science and Technology, 2nd edition. | |
|
Research Abstract |
Dr. Gee is a neuropharmacologist whose principal interests are mechanisms of regulation of signaling through ligand-gated ion channels and the identification of novel signal transduction-based therapeutic strategies for the treatment of disorders amenable to modulation of signal transduction pathways. His laboratory is currently characterizing the pharmacology of several novel allosteric modulatory sites on the GABAA receptor complex and the a7 nicotinic receptor using tissue and recombinantly derived receptors as well as studying the behavioral consequences of modulatory site activation. These sites include for example one for certain neuroactive steroids known as epalons and another for compounds related to the fluoroquinolone antibiotics. The overall mission of the lab is to identify and characterize novel modulatory sites on ligand-gated ion channels, design and synthesize ligands for these sites and evaluate their potential as novel therapeutic agents useful in the treatment of human diseases. PATENTS: Gee KW, Bolger MB, Brinton RE, Burke DJ and McEwen BS: Compositions and methods for alleviating stress, anxiety and seizure activity. Serial No.089,362; 1987. Gee KW, Bolger MB, Brinton RE, Burke D and McEwen, BS: Method, compositions and compounds for modulating brain excitability. U.S. Patent Nos. 5,120,723 and 5,208,227. Bolger, MB, Gee KW, Lan NC, Tahir H, Belelli D, Mirsadeghi S and Purdy R: Methods, compositions and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series. U.S. Patent No. 5,232,917. Bolger MB, Gee KW, Lan NC, Belelli D, Mirsadeghi S, Purdy R and Tahir H. Methods, compositions and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series. U.S. Patent No. 5,591,733. Gee KW and Lan NC: Novel gamma-aminobutyric acid/benzodiazepine receptor and method for determining steroid sites in the gamma-aminobutyric acid/benzodiazepine receptor-chloride ionophore complex. Serial No. 517,194 and 759,512; 1990. Gee KW: Use of peripheral-type benzodiazepine sites for treatment of CNS trauma or disease. U.S. Patent No. 5,550,124. Gee, KW and Lan, NC: Methods and compositions for inducing sleep. Serial No. 08/068,378; 1993. Lan NC, Gee KW, Bolger MB, Tahir H, Purdy R and Upasani RB: Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series. WO 96/16076. Lipkowski A and Gee KW– Substituted Guanidines and the Use Thereof. US Patent Application 09/625,196, Filed: July 21, 2000. Hogenkamp DJ, Johnstone T and Gee KW: Novel quinolones for the treatment of neuropsychiatric disorders. WO 03/97564, Filed June 27, 2002. Hogenkamp DJ, Wang JJ and Gee KW: Novel prodrugs for the oral delivery of amine-containing drugs, amino acids and peptides. US Patent Application 60/493,938, Filed August 8, 2003. Hogenkamp DJ, Johnstone T and Gee KW: Substituted enaminones, their derivatives and uses thereof. US Patent Application 60/569,465, Filed May 6, 2004. Hogenkamp DJ, Gee KW, Johnstone TBC: Substituted enaminones as nicotinic acetylcholine receptor modulators. International application WO 06/138510 A1, published Dec. 28, 2006. Hogenkamp DJ, Johnstone T and Gee KW: Novel quinolones for the treatment of neuropsychiatric disorders. U.S. Patent No. 7,355,047. |
|
| Publications |
Vanover KE, Edgar DM, Seidel WF, Hogenkamp DJ, Fick DB, Lan NC, Gee KW and Carter RB: Response-rate suppression in operant paradigm as predictor of soporific potency in rats and identification of three novel sedative-hypnotic neuroactive steroids. J. Pharm. Exp. Ther. 291:1317-23, 1999. Vanover KE, Suruki M, Robledo S, Huber M, Weiland S, Lan NC, Gee KW, Wood PL and Carter RB: Positive allosteric modulators of the GABAA receptor: differential interaction of benzodiazepines and neuroactive steroids with ethanol. Psychopharmacol. (Berl). 141:77-82, 1999. Vanover KE, Hogenkamp DJ, Lan NC, Gee KW and Carter RB: Behavioral characterization of Co 134444(3?-hydroxy-21-(1'-imidazolyl)-3?-methoxymethyl-5?-pregnan-20-one), a novel sedative-hypnotic neuroactive steroid. Psychopharmacol. (Berl). 155:285-91, 2001. Johnstone TBC, Hogenkamp DJ, Coyne L, Su J, Halliwell RF, Tran MB, Yoshimura RF, Li W-Y, Wang J and Gee KW: Modifying quinolone antibiotics yields new anxiolytics. Nature Medicine 10:31-32, 2004. Wang J, Hogenkamp DJ, Tran M, Li WY, Yoshimura RF, Johnstone TB, Shen WC, Gee KW. Reversible lipidization for the oral delivery of leu-enkephalin. J Drug Target., 14:127-136, 2006. Ng H.J., Whittemore E.R., Tran M.B., Hogenkamp D.J., Broide R.S., Johnstone T.B.C., Zheng L., Stevens K.E. and Gee K.W. A nootropic alpha7 nicotinic receptor allosteric modulator derived from GABAA receptor modulators. Proc. Natl. Acad. Sci. USA, 104:8059-8064, 2007. Hogenkamp D.J., Johnstone T.B.C., Huang J-C., Li W-Y., Tran M., Whittemore E.R., Bagnera R.E. and Gee K.W. Enaminone amides as novel orally active GABAA receptor modulators, J. Med. Chem., 50:3369-3379, 2007. Yoshimura R.F., Hogenkamp D.J., Li W-Y., Tran M., Belluzi J.D., Whittemore E.R., Leslie F.M. and Gee K.W. Negative allosteric modulation of nicotinic acetylcholine receptors blocks nicotine self-administration in rats, J Pharmacol Exp Ther 323:907-915, 2007. |
|
| Grants | National Institute of Mental Health (NIMH) R21 MH080246, 05/09/07-01/31/10. $269,140 direct costs, Optimization of allosteric modulators of nicotinic receptors (Role: P.I.). | |
| National Institute of Mental Health (NIMH) R21 MH082241, 07/01/08-06/30/10, $247,500 direct costs, Non-sedating modulators of GABA-A receptors for anxiety (Role: P.I.). | ||
| Pfizer, Inc., GA0082BG, 02/11/09-02/10/11, $167,713 direct costs, Examination of anxiety-like behavior and seizure susceptibility in mice that over express the A2d-1 protein (Role: Co-Investigator, Dr. David Luo, P.I.). | ||
| National Institute on Aging (NIA) U01 AG032972, 02/01/09-01/31/14, $1,580,866 direct costs, Development of dual GABA-A and alpha7 nicotinic receptor modulators for Alzheimer's Disease (Role: P.I.). | ||
|
Professional Societies |
American Society for Pharmacology and Experimental Therapeutics The Society for Neuroscience American Association for the Advancement of Science Western Pharmacology Society The American Society for Neurochemistry The Endocrine Society |
|
| Graduate Programs |
Pharmacology and Toxicology Interdepartmental Neuroscience Program Medicinal Chemistry and Pharmacology |
|
| Link to this profile | http://www.faculty.uci.edu/profile.cfm?faculty_id=2310 | |
| Last updated | 10/30/2009 | |